Overview

Overview
  • Contact
  • Cathy Turner
    Cathy Turner
    Cathy Turner is Duchenne Programme and TACT Coordinator at the John Walton Muscular Dystrophy Research...

To date the TACT has held 15 review meetings across Europe and the US, and has reviewed a total of 43 program applications from both academic investigators and industry in the following areas: DMD, BMD, SMA, IBM, CMD, NMD, MNGIE  and XLMTM. Of the 43 compounds reviewed 29 were from industry and 14 were from academic applications; 20 were for novel compounds and 23 were for repurposed drugs; 22 were preclinical stage applications and 21 were clinical stage applications. Therefore, TACT believes that it is fulfilling its remit to be an important resource to many different groups at varying stages of the drug development pathway.

All non-confidential summaries from these applications are now available from the TACT section of the TREAT-NMD website.

Looking forward, the dates of the upcoming TACT review meetings have now been confirmed:

16th meeting: Montreal, Canada 24-25th October 2017

17th meeting: Vienna, Austria 4-5th July 2018

Anyone wishing to submit a proposal for these meetings should contact Cathy Turner from the TACT secretariat, as soon as possible.

TACT and the Secretariat would like to gratefully acknowledge the continued support received from patient organisations which make these meetings possible.

If you wish to find out more about TACT you can view a video of a presentation given by Dr Cristina Csimma and Dr Sharon Hesterlee at the Partnering for Cures - Faster Cures Conference in New York City, November 2012. View video here.

 
12 Oct 2017